Immunological aspects of botulinum toxin therapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737175.2017.1262258PMID 27852103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Botulinum toxin drugs: brief history and outlook

  2016cited by this paper
• Strategies for treatment of dystonia

  2016cited by this paper
• Safety aspects of incobotulinumtoxinA high-dose therapy

  2015cited by this paper
• Botulinum neurotoxins: genetic, structural and mechanistic insights

  2014cited by this paper
• Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine

  2014cited by this paper
• Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells.

  2014cited by this paper
• Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A

  2013cited by this paper
• An enzyme‐linked immunosorbent assay for detection of botulinum toxin‐antibodies

  2013cited by this paper
• Five‐year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins

  2012cited by this paper
• Clinical applications of botulinum toxin.

  2012cited by this paper
• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program

  2011cited by this paper
• Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay

  2011cited by this paper
• Evidence for Anterograde Transport and Transcytosis of Botulinum Neurotoxin A (BoNT/A)

  2011cited by this paper
• On muscle spindles, dystonia and botulinum toxin

  2010cited by this paper
• Comparing Botox® and Xeomin® for axillar hyperhidrosis

  2010cited by this paper
• Regulation of Adaptive Immunity by the Innate Immune System

  2010cited by this paper
• Antibody‐Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications

  2010cited by this paper
• Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

  2010cited by this paper
• Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain.

  2009cited by this paper
• Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity

  2009cited by this paper
• Routine use of Xeomin® in patients previously treated with Botox®: long term results

  2009cited by this paper
• Equivalent potency of Xeomin® and BOTOX®

  2008cited by this paper
• Long-Distance Retrograde Effects of Botulinum Neurotoxin A

  2008cited by this paper
• The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves

  2006cited by this paper
• Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®

  2006cited by this paper
• SV2 Is the Protein Receptor for Botulinum Neurotoxin A

  2006cited by this paper
• Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

  2006cited by this paper
• A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia

  2005cited by this paper
• Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia

  2005cited by this paper
• Development of resistance to botulinum toxin type A in patients with torticollis

  2004cited by this paper
• 125I-Labelled botulinum a neurotoxin: Pharmacokinetics in cats after intramuscular injection

  2004cited by this paper
• History of lectins: from hemagglutinins to biological recognition molecules.

  2004cited by this paper
• Ninhydrin sweat test: A simple method for detecting antibodies neutralizing botulinum toxin type A

  2004cited by this paper
• New formulation of BOTOX®

  2004cited by this paper
• Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy

  2004cited by this paper
• Antibody-Induced Failure of Botulinum Toxin Type B Therapy in de novo Patients

  2004cited by this paper
• Regulation of Calcitonin Gene‐Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy

  2004cited by this paper
• Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

  2003cited by this paper
• Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

  2003cited by this paper
• Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells

  2003cited by this paper
• Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia

  2002cited by this paper
• Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies

  2002cited by this paper
• Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses?

  2002cited by this paper
• Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia

  2002cited by this paper
• Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

  2002cited by this paper
• Botulinum toxin type B for treatment of axillar hyperhidrosis

  2002cited by this paper
• Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission.

  2002cited by this paper
• Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis

  2002cited by this paper
• Inhibition of gastric emptying and small intestinal transit by ethanol is mediated by capsaicin-sensitive afferent nerves

  2001cited by this paper
• Botulinum Toxin Antibody Testing: Comparison between the Immunoprecipitation Assay and the Mouse Diaphragm Assay

  2001cited by this paper
• Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

  2001cited by this paper
• Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay

  2000cited by this paper
• The biochemistry of botulinum toxin type B.

  2000cited by this paper
• [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles].

  2000cited by this paper
• Pharmacology of botulinum toxin.

  2000cited by this paper
• Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia

  2000cited by this paper
• Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms.

  2000cited by this paper
• The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans

  2000cited by this paper
• Complete secondary botulinum toxin therapy failure in blepharospasm

  2000cited by this paper
• Can intravenous immunoglobulin improve antibody‐mediated botulinum toxin therapy failure?

  2000cited by this paper
• Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

  2000cited by this paper
• Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.

  1999cited by this paper
• Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

  1999cited by this paper
• Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency

  1999cited by this paper
• Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses.

  1999cited by this paper
• Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response

  1998cited by this paper
• Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin

  1998cited by this paper
• Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A

  1998cited by this paper
• The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.

  1997cited by this paper
• The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A

  1997cited by this paper
• The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans

  1997cited by this paper
• Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection

  1996cited by this paper
• Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release.

  1996cited by this paper
• Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp

  1995cited by this paper
• Tonic vibration reflex and muscle afferent block in writer's cramp

  1995cited by this paper
• Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients.

  1995cited by this paper
• Therapy With Botulinum Toxin

  1995cited by this paper
• Handbook of dystonia

  1995cited by this paper
• Response and immunoresistance to botulinum toxin injections

  1995cited by this paper
• Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.

  1994cited by this paper
• Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin.

  1994cited by this paper
• Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes.

  1994cited by this paper
• Therapy with botulinum toxin

  1994cited by this paper
• Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E.

  1993cited by this paper
• Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

  1993cited by this paper
• Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A

  1993cited by this paper
• Botulinum antibodies in dystonic patients treated with type A botulinum toxin

  1993cited by this paper
• Botulinum A toxin effects on rat jaw muscle spindles.

  1993cited by this paper
• Botulinum neurotoxins serotypes A and E cleave SNAP‐25 at distinct COOH‐terminal peptide bonds

  1993cited by this paper
• Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

  1992cited by this paper
• Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action.

  1992cited by this paper
• Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells.

  1992cited by this paper
• Botulinum toxin treatment of spasmodic torticollis.

  1992cited by this paper
• A double blind trial of botulinum toxin "A" in torticollis, with one year follow up.

  1991cited by this paper
• Botulinum toxin therapy.

  1991cited by this paper
• Botulinum toxin treatment of spasmodic torticollis.

  1988cited by this paper
• Negative antibody response to long-term treatment of facial spasm with botulinum toxin.

  1988cited by this paper
• Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay

  1988cited by this paper
• Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm

  1987cited by this paper
• Absence of antibody production in patients treated with botulinum A toxin.

  1986cited by this paper

• The mouse diaphragm assay in botulinum toxin therapy.

  2026cites this paper
• Developing Botulinum Toxin Drugs: Unexpected Challenges.

  2026cites this paper
• Beyond Structural Divergence: Multiscale Computational Immunogenicity Modelling of Botulinum Neurotoxin E and Cross-Reactivity in Botulinum Neurotoxin A Primed Hosts.

  2025cites this paper
• Meta-Analysis of the Efficacy and Safety Evaluation of Massage Combined with Rehabilitation Training in the Treatment of Post-Stroke Spastic Hemiplegia

  2025cites this paper
• Immunogenicity of botulinum toxin products: the emergence of resistance and ways to overcome it

  2025cites this paper
• Effectiveness of repeated injections of botulinum toxin A on gait and fatigue in adults with spastic paraparesis secondary to multiple sclerosis

  2024cites this paper
• Update on Non-Interchangeability of Botulinum Neurotoxin Products

  2024cites this paper
• NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials

  2024cites this paper
• Botulinum Toxin for the Treatment of Raynaud’s Conditions of the Hand: Clinical Practice Updates and Future Directions

  2024cites this paper
• Immunogenicity of botulinum toxin

  2022cites this paper
• Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations

  2022influential citation
• The Immunology of Botulinum Toxin Therapy: A Brief Summary.

  2022cites this paper
• Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based Review

  2022cites this paper
• Effectiveness and safety of acupuncture for post-stroke spasticity: A systematic review and meta-analysis

  2022cites this paper
• Immunogenicity Associated with Aesthetic Botulinumtoxin A: A Survey of Asia-Pacific Physicians’ Experiences and Recommendations

  2022cites this paper
• Botulinum toxin therapy: past, present and future developments

  2022cites this paper
• Extracorporeal Shock Wave Therapy on Spasticity After Upper Motor Neuron Injury

  2022cites this paper
• Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose

  2021cites this paper
• Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal

  2021cites this paper
• Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review

  2021cites this paper
• Botulinum Neurotoxins as a Therapeutic

  2021cites this paper
• Intravesical Botulinum Toxin for the Treatment of Overactive Bladder

  2020cites this paper
• Botulinum toxin therapy: what do we have and what do we see on the horizon?

  2020cites this paper
• Clinical Pharmacology of Botulinum Toxin Drugs.

  2020cites this paper
• Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

  2020cites this paper
• Clinical duration of action of different botulinum toxin types in humans.

  2020cites this paper
• Adverse Event Profiles of High Dose Botulinum Toxin Injections for Spasticity

  2020cites this paper
• Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.

  2019cites this paper
• In silico mutagenesis: decreasing the immunogenicity of botulinum toxin type A

  2019cites this paper
• Long-term Effects of Extracorporeal Shock Wave Therapy on Poststroke Spasticity: A Meta-analysis of Randomized Controlled Trials.

  2019cites this paper
• Quantifying and Reducing Retained Botulinum Toxin Postinjection

  2019cites this paper
• Immunogenicity Associated with Botulinum Toxin Treatment

  2019influential citation
• Botulinum Toxin Aided Hernia Repair

  2019cites this paper
• An update on new and unique uses of botulinum toxin in movement disorders

  2018cites this paper
• Botulinum Toxin in Abdominal Wall Hernia Repair

  2018cites this paper
• Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity

  2018cites this paper
• Botulinum toxin: State of the art

  2017cites this paper